CO-DEVELOPMENT
Escugen and Sovran To Co-Develop Pan-Tumor Bispecific ADC
The co-developed product combines three mechanisms of action in a single drug.
Read AnnouncementLatest Updates
News & Announcements
COLLABORATION
Escugen and Sovran Form Strategic Partnership
Sovran Bio has entered into a strategic research collaboration aimed at accelerating the development of novel therapeutic candidates across multiple oncology indications.
Read Announcement